Comparing Cisplatin and Gemcitabine with Radiotherapy for Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III clinical trial aims to evaluate the efficacy and safety of concomitant chemo-radiotherapy using either Cisplatin or Gemcitabine as the first line of treatment for patients with locally advanced cervical cancer. The study will enroll 564 patients who will be randomly assigned to receive either Cisplatin or Gemcitabine alongside radiotherapy. The trial will monitor patients over a three-year follow-up period to assess treatment safety and effectiveness, including the evaluation of adverse events and clinical outcomes. The recruitment is planned to occur over four years, with patients receiving treatment in a single hospital center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Singed informed consent.
* Women with Age ≥ 18 years.

  1. -In women of childbearing age it should be documented: a) negative pregnancy test in serum at the beginning of the study (14 days before the start of QT-RT); b) Accept the use of some method of contraception approved by your attending physician during the study and 12 weeks after the treatment has ended.
  2. -In postmenopausal women (surgical or natural menopause) at least one of the following parameters must be met for inclusion.
* Previous bilateral oophorectomy
* Age ≥ 60 years
* Age \<60 years and amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal interval parameters.
* Diagnosis of CaCu EC IB2 mg/dl With histological confirmation (epidermoid, adenocarcinoma or adenoescamoso).
* Patients who are candidates for treatment with concomitant QT / RT.
* ECOG 0-2.
* Measurable disease by CT scan and magnetic resonance imaging of the pelvis according to the RECIST criteria v1.1
* No previous treatment.
* Creatinine clearance ≥ 60 ml / min calculated by the CKD-EPI formula.
* Patients with adequate hematological and hepatic functioning, defined by the following parameters:

  1. Hb equal to or greater than 10g /l. (Transfusion prior to treatment is allowed to reach this level of hemoglobin).
  2. Leukocytes greater than or equal to 4000 / mm3.
  3. Platelets equal to or greater than 100,000mm3.
  4. Total bilirubin ≤1.5 times the upper limit of normal (ULN) and. Transaminases less than 1.5 times the LSN
* Patients with a prior diagnosis of the following comorbidities:

  * Diabetes mellitus type 2, which has: fasting serum glucose \<250 mg/dl.
  * Systemic arterial hypertension G1 or G2 according to CTCAE v4.03
  * Child Pugh A liver disease
  * Cardiovascular diseases such as: Ischemic heart disease undergoing asymptomatic treatment, without clinical data of stable or unstable angina or for acute myocardial infarction.
  * Compensated heart failure in functional class I of the New York Heart Association.
  * Systemic Lupus Erythematosus with mild or inactive lupus activity (less than or equal to 4 points according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).

Exclusion Criteria:

* Patients with a second neoplasm.
* Pregnant or lactating patients.
* Patients with small cell and / or neuroendocrine CaCu.
* Patients with impaired renal function with a GFR \<or equal to 60ml / min calculated by the CKD-EPI formula
* Patients with a history of active TB (TB)
* Patients with a history of Human Immunodeficiency Virus (HIV) infection
* Patients with vesico-vaginal or vesicorectal fistulas at diagnosis
* Concomitant treatment with another experimental drug. Social, family or geographical conditions that suggest a poor attachment to the study

Criteria Interruption of Treatment (Withdrawal of patients)

A patient will be discontinued from the study under the following circumstances:

* Evidence of disease progression.
* If treating physician considers that a change of therapy may benefit the patient.
* If patient withdrew consent
* Due to unmanageable toxicity By pregnancy or if the patient does not wish to continue using the contraceptive methods indicated by the attending physician

Where it's running

• National Cancer Institute of Mexico
  Mexico City, Mexico City, Mexico Recruiting

Study contacts

• Principal investigator: Lucely C Cetina, MSc, PhD — National Cancer Institute of Mexico
• Study coordinator: Lucely C Cetina, MD, MSc
• Email: lucelycetina.incan@gmail.com
• Phone: +5215531952791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Vitamin D Status and Outcomes in Locally Advanced Cervical Cancer treated with chemoradiotherapy

  This study tests whether pretreatment vitamin D levels can predict how well women with locally advanced cervical cancer respond to standard chemoradiotherapy.

  Recruiting University of Kragujevac · Kragujevac, Šumadija · NCT07743918

• Gemcitabine, Docetaxel, Melphalan, and Carboplatin with a Second Transplant in Young Patients with Relapsed Germ Cell Tumors

  This study tests whether a tandem autologous stem cell transplant with GemDMC, followed by CE, can help children and teens with relapsed or refractory germ cell tumors.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07662018

• Patient-tailored 3D-printed ARCHITECT applicator for cervical cancer brachytherapy

  We’re testing a 3D-printed, one-time use ARCHITECT applicator to see if it safely helps deliver brachytherapy for locally advanced cervical cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07435987

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• Olive oil mouthwash to reduce mouth sores from head and neck cancer treatment

  This will try olive oil mouthwash to see if it reduces mouth sores in adults getting radiotherapy or chemoradiotherapy for head and neck cancer.

  Recruiting Chiayi Christian Hospital · Chiayi City, Chia-Yi City · NCT07293013

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.